Safety Profile of Liver FibroScan in Patients with Cardiac Pacemakers or Implantable Cardioverter-Defibrillators
Background. Emerging evidence suggests that nonalcoholic fatty liver disease (NAFLD) is associated with coronary artery diseases and arrhythmias. The FibroScan (Echosens, France), a widely available, noninvasive device, is able to detect liver fibrosis and steatosis within this patient population. H...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Canadian Journal of Gastroenterology and Hepatology |
| Online Access: | http://dx.doi.org/10.1155/2017/7298032 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832557058089549824 |
|---|---|
| author | Yin Chan Stephanie Pranke Farid Rashidi Shravan Nosib Lawrence Worobetz |
| author_facet | Yin Chan Stephanie Pranke Farid Rashidi Shravan Nosib Lawrence Worobetz |
| author_sort | Yin Chan |
| collection | DOAJ |
| description | Background. Emerging evidence suggests that nonalcoholic fatty liver disease (NAFLD) is associated with coronary artery diseases and arrhythmias. The FibroScan (Echosens, France), a widely available, noninvasive device, is able to detect liver fibrosis and steatosis within this patient population. However, the FibroScan is currently contraindicated in patients with cardiac pacemakers (PM) or implantable cardioverter-defibrillators (ICD). Objective. To determine the safety profile of FibroScan testing in patients with PM or ICD. Methods. Consecutive outpatients undergoing routine device interrogations at a tertiary level teaching hospital underwent simultaneous liver stiffness measurements. PM or ICD performance data, device types, patient demographics, medical history, and previous laboratory and conventional liver imaging results were collected. Results. Analysis of 107 subjects with 33 different types of implanted cardiac devices, from 5 different companies (Medtronic, Sorin, ELA Medical, Boston Scientific, and St. Jude), did not demonstrate any adverse events as defined by abnormal device sensing/pacing or ICD firing. This population included high risk subjects undergoing active pacing (n=53) and with right pectoral PM placement (n=1). None of the subjects had any clinical signs of decompensated congestive heart failure or cirrhosis during the exam. Conclusion. TE with FibroScan can be safely performed in patients with PM or ICD. |
| format | Article |
| id | doaj-art-d25205f989b74be7b68e2ddd643df975 |
| institution | Kabale University |
| issn | 2291-2789 2291-2797 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Gastroenterology and Hepatology |
| spelling | doaj-art-d25205f989b74be7b68e2ddd643df9752025-02-03T05:43:42ZengWileyCanadian Journal of Gastroenterology and Hepatology2291-27892291-27972017-01-01201710.1155/2017/72980327298032Safety Profile of Liver FibroScan in Patients with Cardiac Pacemakers or Implantable Cardioverter-DefibrillatorsYin Chan0Stephanie Pranke1Farid Rashidi2Shravan Nosib3Lawrence Worobetz4Division of Gastroenterology, Department of Medicine, University of Saskatchewan, Saskatoon, SK, CanadaDivision of Gastroenterology, Department of Medicine, University of Saskatchewan, Saskatoon, SK, CanadaDepartment of Medical Imaging, University of Saskatchewan, Saskatoon, SK, CanadaDivision of Cardiology, Department of Medicine, University of Saskatchewan, Saskatoon, SK, CanadaDivision of Gastroenterology, Department of Medicine, University of Saskatchewan, Saskatoon, SK, CanadaBackground. Emerging evidence suggests that nonalcoholic fatty liver disease (NAFLD) is associated with coronary artery diseases and arrhythmias. The FibroScan (Echosens, France), a widely available, noninvasive device, is able to detect liver fibrosis and steatosis within this patient population. However, the FibroScan is currently contraindicated in patients with cardiac pacemakers (PM) or implantable cardioverter-defibrillators (ICD). Objective. To determine the safety profile of FibroScan testing in patients with PM or ICD. Methods. Consecutive outpatients undergoing routine device interrogations at a tertiary level teaching hospital underwent simultaneous liver stiffness measurements. PM or ICD performance data, device types, patient demographics, medical history, and previous laboratory and conventional liver imaging results were collected. Results. Analysis of 107 subjects with 33 different types of implanted cardiac devices, from 5 different companies (Medtronic, Sorin, ELA Medical, Boston Scientific, and St. Jude), did not demonstrate any adverse events as defined by abnormal device sensing/pacing or ICD firing. This population included high risk subjects undergoing active pacing (n=53) and with right pectoral PM placement (n=1). None of the subjects had any clinical signs of decompensated congestive heart failure or cirrhosis during the exam. Conclusion. TE with FibroScan can be safely performed in patients with PM or ICD.http://dx.doi.org/10.1155/2017/7298032 |
| spellingShingle | Yin Chan Stephanie Pranke Farid Rashidi Shravan Nosib Lawrence Worobetz Safety Profile of Liver FibroScan in Patients with Cardiac Pacemakers or Implantable Cardioverter-Defibrillators Canadian Journal of Gastroenterology and Hepatology |
| title | Safety Profile of Liver FibroScan in Patients with Cardiac Pacemakers or Implantable Cardioverter-Defibrillators |
| title_full | Safety Profile of Liver FibroScan in Patients with Cardiac Pacemakers or Implantable Cardioverter-Defibrillators |
| title_fullStr | Safety Profile of Liver FibroScan in Patients with Cardiac Pacemakers or Implantable Cardioverter-Defibrillators |
| title_full_unstemmed | Safety Profile of Liver FibroScan in Patients with Cardiac Pacemakers or Implantable Cardioverter-Defibrillators |
| title_short | Safety Profile of Liver FibroScan in Patients with Cardiac Pacemakers or Implantable Cardioverter-Defibrillators |
| title_sort | safety profile of liver fibroscan in patients with cardiac pacemakers or implantable cardioverter defibrillators |
| url | http://dx.doi.org/10.1155/2017/7298032 |
| work_keys_str_mv | AT yinchan safetyprofileofliverfibroscaninpatientswithcardiacpacemakersorimplantablecardioverterdefibrillators AT stephaniepranke safetyprofileofliverfibroscaninpatientswithcardiacpacemakersorimplantablecardioverterdefibrillators AT faridrashidi safetyprofileofliverfibroscaninpatientswithcardiacpacemakersorimplantablecardioverterdefibrillators AT shravannosib safetyprofileofliverfibroscaninpatientswithcardiacpacemakersorimplantablecardioverterdefibrillators AT lawrenceworobetz safetyprofileofliverfibroscaninpatientswithcardiacpacemakersorimplantablecardioverterdefibrillators |